Literature DB >> 24510513

Long-term outcome of sensorineural hearing loss in nasopharyngeal carcinoma patients: comparison between treatment with radiotherapy alone and chemoradiotherapy.

Yumei Wei1, Tao Zhou, Jian Zhu, Yi Zhang, Mingping Sun, Xiuping Ding, Dongqing Wang, Hongsheng Li, Baosheng Li.   

Abstract

The purpose of this study is to assess the long-term effect of sensorineural hearing loss (SNHL) resulted from radiotherapy (RT) alone versus chemoradiotherapy in nasopharyngeal carcinoma patients (NPC). Seventy-two patients initially diagnosed with NPC were enrolled from Shandong Tumor Hospital between March 2003 and May 2007. They were assigned into two groups: RT alone and chemoradiotherapy according to the different treatment regimens. Intensity-modulated radiation therapy was applied for both groups, concurrent and adjuvant cisplatin were administered for chemoradiotherapy group additionally. Hearing threshold test was performed at various time periods after completion of RT. Mean radiation dose to the cochlea in each ear was calculated to determine the correlation between cochlear dose and SNHL. We found that the hearing loss is more severe in the chemoradiotherapy group compared with RT group, from completion of RT up to the 5 years of follow-up period. This is especially obvious in the high frequency range. Hearing level is seriously damaged when cochlea dose exceeds 46 GY. We concluded that concurrent/adjuvant chemotherapy plus RT aggravates SNHL in NPC patients than RT alone and thus inner ear tissue tolerance should be redefined in those patients.

Entities:  

Mesh:

Year:  2014        PMID: 24510513     DOI: 10.1007/s12013-014-9814-x

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  7 in total

1.  SmartArc-based volumetric modulated arc therapy can improve the middle ear, vestibule and cochlea sparing for locoregionally advanced nasopharyngeal carcinoma: a dosimetric comparison with step-and-shoot intensity-modulated radiotherapy.

Authors:  J Gao; T-L Qian; C-Z Tao; Y-H Zhang; Y Zhou; J Yang; J He; R Wang; P-J Zhou
Journal:  Br J Radiol       Date:  2015-06-25       Impact factor: 3.039

2.  The effectiveness of myringotomy and ventilation tube insertion versus observation in post-radiation otitis media with effusion.

Authors:  Paninee Charusripan; Likhit Khattiyawittayakun
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-05-24       Impact factor: 2.503

3.  Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing : Retrospective analysis of 29 medulloblastoma patients.

Authors:  Sergiu Scobioala; Ross Parfitt; Peter Matulat; Christopher Kittel; Fatemeh Ebrahimi; Heidi Wolters; Antoinette Am Zehnhoff-Dinnesen; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2017-09-08       Impact factor: 3.621

4.  Sensorineural Hearing Loss after Combined Intensity Modulated Radiation Therapy and Cisplatin-Based Chemotherapy for Nasopharyngeal Carcinoma.

Authors:  Jin Wang; Yuan-Yuan Chen; An Tai; Xue-Lin Chen; Shao-Ming Huang; Cungen Yang; Yong Bao; Ning-Wei Li; Xiao-Wu Deng; Chong Zhao; Ming Chen; X Allen Li
Journal:  Transl Oncol       Date:  2015-12       Impact factor: 4.243

5.  Vestibulotoxicity Associated With Platinum-Based Chemotherapy in Survivors of Cancer: A Scoping Review.

Authors:  Pattarawadee Prayuenyong; John A Taylor; Stephanie E Pearson; Rachel Gomez; Poulam M Patel; Deborah A Hall; Anand V Kasbekar; David M Baguley
Journal:  Front Oncol       Date:  2018-09-25       Impact factor: 6.244

6.  Effect of Hydrogen Inhalation Therapy on Hearing Loss of Patients With Nasopharyngeal Carcinoma After Radiotherapy.

Authors:  Xiaofeng Kong; Tianyu Lu; You-Yong Lu; Zhinan Yin; Kecheng Xu
Journal:  Front Med (Lausanne)       Date:  2022-03-31

7.  Definition of an Normal Tissue Complication Probability Model for the Inner Ear in Definitive Radiochemotherapy of Nasopharynx Carcinoma.

Authors:  Leonie Peuker; Daniel Rolf; Michael Oertel; Alexander Peuker; Sergiu Scobioala; Dominik Hering; Claudia Rudack; Uwe Haverkamp; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2022-07-14       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.